Navigation Links
Preventing or reducing enlarged heart decreases risk of heart failure
Date:9/13/2007

NEW YORK (Sept. 10, 2007) -- For high-blood-pressure patients, preventing or reducing enlarged heart (left ventricular hypertrophy or LVH) reduces risk of heart failure. The study is published in the Sept. 4 Annals of Internal Medicine and led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City.

An estimated 20 percent of all high-blood-pressure patients, or 12 million Americans, have LVH and are at increased risk of developing heart failure.

While the direct relationship between levels of LVH in patients with high blood pressure and risk of cardiac complications -- including death, heart attack, stroke and atrial fibrillation -- has previously been demonstrated by NewYork-Presbyterian/Weill Cornell researchers (JAMA, 2004 and 2006), the new study is the first to demonstrate that prevention or regression of LVH reduces risk of being hospitalized for heart failure -- and that this relationship exists independent of therapy type and the benefits of blood pressure reduction. The study uses data from the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study conducted between 1995 and 2001.

"The message for high-blood-pressure patients is that by preventing or reversing enlarged heart, there is an added benefit, over and above any reduction in blood pressure, of lowering risk for heart failure," says the study's principal investigator, Dr. Peter Okin, director of clinical affairs and professor of medicine in the Greenberg Division of Cardiology at Weill Cornell Medical College and a cardiologist at NewYork-Presbyterian/Weill Cornell.

"And, from a public health perspective, our findings suggest that blood-pressure therapy targeted at regression or prevention of LVH may help to blunt the increasing incidence of heart failure," continues Dr. Okin.

Of the 8,479 high-blood-pressure patients without heart failure followed in the new study, 214 were hospitalized for heart failure (2.5 percent). Among these patients, a greater than average reduction of LVH was associated with a 43-percent reduced risk of heart failure, and remained associated with a 36-percent reduced risk after adjusting for other risk factors. Levels of LVH were determined by electrocardiograph (ECG) using Cornell voltage-duration product criteria. (Cornell voltage-duration product, an ECG pattern associated with presence of LVH, was developed at Weill Cornell Medical College in 1992 and is currently in use worldwide.)

Previous studies have shown that hypertension doubles the lifetime risk for developing heart failure in men and triples the risk in women, accounting for 39 percent of new heart failure cases in men and 59 percent of incident cases in women.

All patients in the LIFE study received Losartan- or atenolol-based therapies. In a previous LIFE study paper (Circulation, 2003), Weill Cornell researchers found the angiotensin receptor antagonist drug Losartan had a decided advantage over another anti-hypertensive drug, the beta-blocker atenolol, in reducing LVH.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Preventing mental decline in the aged
2. Preventing white coat hypertension
3. Green tea beneficial in preventing osteoarthritis
4. Preventing Childhood Deaths
5. Preventing Vision Loss
6. Preventing Vision Loss
7. Preventing Colorectal Cancer
8. Preventing Prostate Cancer
9. Lycopene Can Help In Preventing Prostate Cancer
10. Heart Drug Also Effective In Preventing Specific Causes Of Death
11. Preventing cavities in children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... May 03, 2016 , ... With the opioid epidemic now ... excessive levels of alcohol use. Alcohol and its misuse causes long-term consequences for ... the susceptibility to strokes in those 65 years and older. In addition, there ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... process that selects DNA or RNA from a random library of sequences depending ... used as drugs or diagnostic agents. SELEX selection is commonly performed using filters, ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... hired award-winning creative director Joe Ferrazano to serve in the newly created position ... will be overseeing the agency’s creative efforts in the Chicago and LA offices. ...
(Date:5/3/2016)... ... ... Elizabeth Murray has always loved walking one to two miles a day. ... and one on her arm. But she got to the point where she could ... , The valves of the heart wouldn’t close properly resulting in mitral regurgitation, where ...
(Date:5/3/2016)... ... May 03, 2016 , ... Excessive panting in the car ... anxiety. "Pet owners often think anxiety only manifests itself as trembling or ‘tail ... ways, and there’s things that be done about it,” says Dr. Jim Lowe, technical ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016 Acquisition ... Sciences, Product Development Capabilities in North ... Base . Indegene ( http://www.indegene.com ... the acquisition of Skura Corporation,s life science business. ... adaptive sales enablement technology for life science organizations ...
(Date:4/28/2016)... April 28, 2016   Click here for ... Inc. (NYSE: DPLO), the nation,s largest independent specialty ... definitive agreement to acquire Valley Campus Pharmacy, Inc., ... a leading specialty pharmacy that provides individualized patient ... . In 2015, TNH generated approximately $400 ...
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
Breaking Medicine Technology: